Live Evaluations
Prurigo Nodularis: Managing the ‘Itch-Scratch Cycle’ with Biologics
About
Prurigo Nodularis: Managing the ‘Itch-Scratch Cycle’ with Biologics
This activity is supported by educational grants from Galderma and Sanofi and Regeneron Pharmaceuticals.
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the impact of PN on patient quality of life, including sleep quality and mental health
Review efficacy and safety data for approved and emerging biologics to manage PN
Discuss patient-centered strategies for integrating new and emerging biologics for PN into clinical care
Intended Audience
Faculty
Raj Chovatiya, MD, PhD, MSCI
Clinical Associate Professor, Rosalind Franklin University Chicago Medical School, Founder and Director, Center for Medical Dermatology and Immunology Research
Chicago, IL
Sarina Elmariah, MD, PhD, MPH
Director, UCSF Itch and Neurosensory Center
Associate Professor of Dermatology
University of California San Francisco
San Francisco, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Consultant: AbbVie, Arcutis, Arena, Argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, L’Oréal, National Eczema Association, Pfizer Inc., Regeneron, Sanofi, and UCB
Speakers’ Bureau or Honoraria: AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer Inc., Regeneron, Sanofi, and UCB
Advisory Board: Bellus Health, Galderma, Pfizer, Sanofi Regeneron, Trevi Therapeutics
Speaker's Bureau: Eli Lilly, Pfizer
Ownership Interest: Frontier Bio
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.